Want to join the conversation?
$LRCX 4Q15 Call: We demonstrated our commitment to long-term profitable growth and return value to shareholders with a 16% growth in net income fiscal YoverY and $630MM or three times increase YoverY of return value to shareholders through buybacks and dividends.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.